The classic website will no longer be available as of June 25, 2024. Please use the modernized
Working… Menu

Validation of a Mobile Phone Based on EPRO Tool in Subjects With Systemic Lupus Erythematosus (VALUE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03142711
Recruitment Status : Completed
First Posted : May 5, 2017
Last Update Posted : November 7, 2023
Ampel BioSolutions, LLC
Information provided by (Responsible Party):
Lupus Research Alliance

Brief Summary:
Systemic lupus erythematosus (SLE) may involve a variety of organ systems expressed differently from patient to patient, and so can be difficult to characterize clinically. Patient reported outcomes (PROs), which consist of feedback directly from patients regarding their symptoms without interpretation by a clinician, are typically used in SLE to supplement other clinical measures. Standard PROs typically used in SLE include the 36-item short form health survey (SF-36), the functional assessment of chronic illness therapy - fatigue (FACIT-F), and the patient global assessment (PtGA), administered by paper or electronic tablet during the clinic visits. The recent development of electronic mobile device technology, such as the smartphone, has made it possible to collect PRO information away from the clinical site in the subject's environment. This study will assess by measurement equivalence testing whether data collected via a smartphone are comparable to that collected in standard fashion and whether PROs obtained in the subject's environment may be more informative than that collected in the physician's office on paper.

Condition or disease Intervention/treatment
SLE Lupus Erythematosus, Systemic Systemic Lupus Erythematosus Other: No Medical Intervention

Layout table for study information
Study Type : Observational
Actual Enrollment : 80 participants
Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Validation of a Mobile Phone Based on EPRO Tool in Subjects With Systemic Lupus Erythematosus
Actual Study Start Date : August 21, 2017
Actual Primary Completion Date : July 3, 2018
Actual Study Completion Date : July 3, 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lupus

Intervention Details:
  • Other: No Medical Intervention
    Validation of phone ePRO

Primary Outcome Measures :
  1. ePRO Validation [ Time Frame: 7 months ]
    To evaluate measurement equivalence between the two PRO data collection modes - original paper mode versus the ePRO application on a handheld mobile phone for the following PRO's: SF-36 HRQoL questionnaire, the FACIT-F fatigue instrument, and the PtGA. The three PROs will be administered on clinic days by both modes: paper and ePRO. Concurrent results will be compared, and percentage similarities calculated.

Biospecimen Retention:   Samples With DNA
Blood and Urine samples

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients with SLE.

Inclusion Criteria:

  1. Willing and able to provide written informed consent
  2. Males or females, aged 18 years or older
  3. Classification of SLE by either the American College of Rheumatology (ACR) or Systemic Lupus International Collaborating Clinics Classification (SLICC) criteria
  4. On a stable SLE treatment regimen consisting of any of the following medications for a period of at least 30 days prior to Screening

    • Corticosteroids (<30 mg prednisone or equivalent per day)
    • Hydroxychloroquine or equivalent anti-malarial
    • Other immunosuppressive or immunomodulatory agents including methotrexate, azathioprine, leflunomide, mycophenolate (including mycophenolate mofetil or sodium), cyclophosphasmide, belimumab, calcineurin inhibitors (e.g. tacrolimus, cyclosporine)
  5. Willing to perform and comply with all study procedures, including attending clinic visits at Baseline, Month 1, and Month 2 as scheduled

Exclusion Criteria:

  1. Rapidly progressive neurologic disease
  2. Cognitive dysfunction that might interfere with the capacity to use the ePRO device
  3. Any condition that might in the investigator's opinion might preclude completion of the study
  4. Current drug or alcohol abuse or dependence, or a history of drug or alcohol abuse or dependence within 1 year prior to Screening
  5. Clinical evidence of significant unstable or uncontrolled acute or chronic diseases not caused by SLE (e.g., diabetes, cardiovascular, pulmonary, hematologic, gastrointestinal, neurological, or infectious) which, in the opinion of the Investigator, could confound the results of the study or put the subject at undue risk.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03142711

Layout table for location information
United States, Georgia
Emory University
Atlanta, Georgia, United States, 30303
United States, Massachusetts
Brigham and Women's HospitL
Boston, Massachusetts, United States, 02115
United States, New York
Northwell Health
Great Neck, New York, United States, 11021
United States, Pennsylvania
Allegheny Health Network
Pittsburgh, Pennsylvania, United States, 15212
United States, Tennessee
Vanderbilt University Medical Center
Nashville, Tennessee, United States, 37232
Canada, Alberta
University of Alberta
Edmonton, Alberta, Canada, T6G 2S2
Canada, Manitoba
University of Manitoba
Winnipeg, Manitoba, Canada, R3A 1M4
Canada, Ontario
McMaster University Medical Centre
Hamilton, Ontario, Canada, L8S 4K1
University of Western Ontario/St. Joseph's Healthcare
London, Ontario, Canada, N6A 4V2
Canada, Quebec
McGill University Health Centre
Montréal, Quebec, Canada, H3G 1A4
Sponsors and Collaborators
Lupus Research Alliance
Ampel BioSolutions, LLC
Layout table for additonal information
Responsible Party: Lupus Research Alliance Identifier: NCT03142711    
Other Study ID Numbers: AMP-003
First Posted: May 5, 2017    Key Record Dates
Last Update Posted: November 7, 2023
Last Verified: November 2023
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Lupus Erythematosus, Systemic
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases